Back to Search Start Over

Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.

Authors :
Verlooy, J
Mosseri, V
Bracard, S
Tubiana, A Lellouch
Kalifa, C
Pichon, F
Frappaz, D
Chastagner, P
Pagnier, A
Bertozzi, A-I
Gentet, J C
Sariban, Eric
Rialland, X
Edan, C
Bours, D
Zerah, M
Le Gales, C
Alapetite, C
Doz, F
Verlooy, J
Mosseri, V
Bracard, S
Tubiana, A Lellouch
Kalifa, C
Pichon, F
Frappaz, D
Chastagner, P
Pagnier, A
Bertozzi, A-I
Gentet, J C
Sariban, Eric
Rialland, X
Edan, C
Bours, D
Zerah, M
Le Gales, C
Alapetite, C
Doz, F
Source :
European journal of cancer, 42 (17
Publication Year :
2006

Abstract

AIM: Improvement of EFS of children older than 3 years with high risk medulloblastoma. METHODS: Between 1993 and 1999, 115 patients (3-18 years, mean 8 years) with high risk medulloblastoma were included. After surgery treatment consisted of chemotherapy ('8in1' and etoposide/carboplatin) before and after craniospinal radiotherapy. RESULTS: Patients were staged using Chang-criteria (PF residue only, M1 and M2/M3) by local investigator as well as by central review panel (82.4% concordance). Chemotherapy was well tolerated without major delays in radiotherapy. With a mean follow up of 81 months (9-119), 5-year EFS was 49.8% and OS 60.1%. In detail according to subgroups EFS was 68.8% for PF residue only, 58.8% for M1 disease and 43.1% for M2/M3. CONCLUSION: M1 patients are legitimate high risk patients. Survival rates are still very low for high risk medulloblastoma patients and future trials should therefore focus on more intensive (chemotherapy/radiotherapy) treatment.<br />Journal Article<br />Research Support, Non-U.S. Gov't<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published

Details

Database :
OAIster
Journal :
European journal of cancer, 42 (17
Notes :
1 full-text file(s): application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1363712389
Document Type :
Electronic Resource